Streetbeat News

Products Services

SLDB

Solid Biosciences Inc. announced that the FDA has granted Rare Pediatric Disease Designation to its Duchenne muscular dystrophy gene therapy candidate, SGT-003. This designation is a significant step for the company, which focuses on developing precision genetic medicines for neuromuscular and cardiac diseases.

Portfolio Pulse from Benzinga Newsdesk

April 01, 2024 | 11:48 am

CNTX

Context Therapeutics has submitted an FDA Investigational New Drug application to start a Phase 1 trial of CTIM-76 for treating Claudin 6-positive gynecologic and testicular cancers. This marks a significant step in the company's efforts to address these specific cancer types.

Portfolio Pulse from Benzinga Newsdesk

April 01, 2024 | 11:46 am

BMY

ZLAB

Zai Lab's stock price increased following the announcement that its partner, Bristol Myers Squibb, reported the KRYSTAL-12 confirmatory trial evaluating KRAZATI met its primary endpoint on March 28.

Portfolio Pulse from Charles Gross

April 01, 2024 | 11:34 am

GOGO

Gogo Business Aviation has partnered with Atlas Air Service to develop the first European Supplemental Type Certificate (STC) for the Gogo Galileo HDX antenna for the Cessna CitationJet series and another STC for the Embraer Phenom 300. This partnership aims to enhance connectivity solutions for light jet aircraft in Europe.

Portfolio Pulse from Benzinga Newsdesk

April 01, 2024 | 11:32 am

GOOGL

Google's Gmail celebrated its 20th anniversary, marking two decades since its launch on April Fool's Day by co-founders Larry Page and Sergey Brin. Initially thought to be a prank, Gmail revolutionized email services by offering 1 gigabyte of storage per account, a significant leap from the storage offered by other services at the time. Today, Gmail has approximately 1.8 billion active accounts with 15 gigabytes of free storage each. The service's success led to the development of other Google services like Google Maps, Google Docs, and the acquisition of YouTube. Gmail's introduction also marked the beginning of Google's strategy to use digital surveillance to sell more ads. Recently, Google began experimenting with AI enhancements for Gmail, including free AI cyber tools to combat online threats.

Portfolio Pulse from Benzinga Neuro

April 01, 2024 | 11:30 am

OCUP

VTRS

Ocuphire Pharma, Inc. (OCUP) and its partner Viatris Inc. (VTRS) have announced the U.S. commercial launch of RYZUMVI (phentolamine ophthalmic solution 0.75%). Ocuphire, a clinical-stage biopharmaceutical company, has a global license agreement with Viatris to co-develop and commercialize the solution, making Ocuphire eligible for regulatory and commercial milestones as well as royalties.

Portfolio Pulse from Benzinga Newsdesk

April 01, 2024 | 11:17 am

BAX

Baxter International Inc. (NYSE:BAX) has received U.S. FDA 510(k) clearance for its Novum IQ large volume infusion pump (LVP) with Dose IQ Safety Software, expanding its Novum IQ Infusion Platform. This approval enhances Baxter's infusion therapy offerings by allowing clinicians to use a unified system across different patient care settings, showcasing Baxter's ongoing innovation in the field.

Portfolio Pulse from Benzinga Newsdesk

April 01, 2024 | 11:16 am

GILT

Gilat Satellite Networks Ltd. (GILT) has received over $13M in additional orders from various satellite operators for its SkyEdge IV and SkyEdge II-c platforms. These orders are part of ongoing strategic partnerships and will support services such as in-flight connectivity, maritime mobility, cellular backhaul, and fixed data services.

Portfolio Pulse from Benzinga Newsdesk

April 01, 2024 | 11:12 am

CMCSA

ROKU

WMT

Walmart announced updates on Walmart Connect, emphasizing its partnerships with NBCUniversal, Roku, and TikTok to enhance omnichannel connections. This move aims to leverage Walmart's extensive retail network and digital platforms to offer more integrated advertising solutions.

Portfolio Pulse from Charles Gross

April 01, 2024 | 11:09 am

QNCX

Quince Therapeutics reported a strong cash position of $75.1M as of December 31, 2023, which is expected to fully fund its lead asset, EryDex, through Phase 3 NEAT topline results and prepare for a potential NDA submission in 2026. The company is also exploring strategic partnerships to out-license EryDex in ex-U.S. regions to extend its operational runway.

Portfolio Pulse from Benzinga Newsdesk

April 01, 2024 | 11:08 am